Press releases

ORYZON receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies

ORYZON to provide corporate progress updates at several events in October

ORYZON to give updates on corporate progress in September

Oryzon announces completed patient recruitment in the PORTICO Phase IIb trial of vafidemstat in Borderline Personality Disorder

ORYZON reports financial results and corporate updates for half-year ending June 30, 2023

Positive aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders

Positive preclinical data of ORY-4001 for the treatment of Charcot-Marie-Tooth (CMT) disease presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

ORYZON to present positive preclinical efficacy data of ORY-4001 in Charcot-Marie-Tooth (CMT) disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

ORYZON to present trial in progress Phase Ib FRIDA study at the upcoming 2023 ASCO annual meeting